162 related articles for article (PubMed ID: 7044632)
1. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
Bendich A; Kafkewitz D; Abuchowski A; Davis FF
Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of blastogenesis by native and polyethylene glycol-modified asparaginases from Escherichia coli and Vibrio succinogenes.
Bendich A; Kafkewitz D; Abuchowski A; Davis FF
Immunol Commun; 1983; 12(3):273-84. PubMed ID: 6350165
[TBL] [Abstract][Full Text] [Related]
3. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.
Abuchowski A; Kazo GM; Verhoest CR; Van Es T; Kafkewitz D; Nucci ML; Viau AT; Davis FF
Cancer Biochem Biophys; 1984 Jun; 7(2):175-86. PubMed ID: 6467175
[TBL] [Abstract][Full Text] [Related]
4. Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Nishimura H; Matsushima A; Inada Y
Gan; 1982 Jun; 73(3):470-4. PubMed ID: 6751921
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes.
Durden DL; Distasio JA
Cancer Res; 1980 Apr; 40(4):1125-9. PubMed ID: 6986981
[No Abstract] [Full Text] [Related]
6. Enzyme-induced asparagine and glutamine depletion and immune system function.
Kafkewitz D; Bendich A
Am J Clin Nutr; 1983 Jun; 37(6):1025-30. PubMed ID: 6342356
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
8. Studies on the immunosuppressive activity of L-asparaginase.
Marai R; Guyonnet JC; Julou L; De Ratuld Y; Werner GH
Recent Results Cancer Res; 1970; 33():160-9. PubMed ID: 4949160
[No Abstract] [Full Text] [Related]
9. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
Roberts J; Schmid FA; Old LJ; Stockert E
Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes.
Distasio JA; Niederman RA; Kafkewitz D; Goodman D
J Biol Chem; 1976 Nov; 251(22):6929-33. PubMed ID: 11211
[TBL] [Abstract][Full Text] [Related]
13. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
Saito T; Ueno T; Sekine T; Kodera Y; Hiroto M; Matsushima A; Nishimura H; Inada Y
Leukemia; 1997 Apr; 11 Suppl 3():408-9. PubMed ID: 9209407
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific ell-mediated cytotoxicity.
Durden DL; Distasio JA
Int J Cancer; 1981 Jan; 27(1):59-65. PubMed ID: 7019106
[No Abstract] [Full Text] [Related]
15. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity.
Distasio JA; Salazar AM; Nadji M; Durden DL
Int J Cancer; 1982 Sep; 30(3):343-7. PubMed ID: 6752048
[No Abstract] [Full Text] [Related]
16. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Park YK; Abuchowski A; Davis S; Davis F
Anticancer Res; 1981; 1(6):373-6. PubMed ID: 7046623
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
Ashworth LA; MacLennan AP
Cancer Res; 1974 Jun; 34(6):1353-9. PubMed ID: 4596965
[No Abstract] [Full Text] [Related]
18. Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.
Abuchowski A; van Es T; Palczuk NC; McCoy JR; Davis FF
Cancer Treat Rep; 1979 Jun; 63(6):1127-32. PubMed ID: 466651
[TBL] [Abstract][Full Text] [Related]
19. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to polyethylene glycol modified L-asparaginase in mice.
Kawamura K; Igarashi T; Fujii T; Kamisaki Y; Wada H; Kishimoto S
Int Arch Allergy Appl Immunol; 1985; 76(4):324-30. PubMed ID: 3980111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
